Study Comparing Two Types of Psychotherapy for Treating Depression and Substance Abuse - Full Text View

Purpose

The purpose of this study is to determine whether Integrated Cognitive Behavioral Therapy or Twelve Step Facilitation Therapy is most effective for treatment of dually diagnosed veterans with depressive and substance use disorders.

Condition	Intervention
Major Depressive Disorder Alcohol Abuse Cannabis Abuse Substance-Related Disorders	Behavioral: Integrated Cognitive Behavioral Therapy Behavioral: Twelve Step Facilitation Therapy

MedlinePlus related topics:

Depression

ChemIDplus related topics:

Cannabis GW-1000 Ethanol

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study

Official Title:	Integrated CBT for Substance Use and Depressive Disorders

Further study details as provided by Department of Veterans Affairs:

Study Start Date:	October 2004
Estimated Study Completion Date:	September 2008

Detailed Description:

Depression is the most frequent co-occuring mental health disorder among adults with substance use disorders, and such comorbidity is often associated with poorer treatment outcomes. Although there is an urgent need for effective treatments specific for dual-diagnosis adults, few studies have been conducted to address this need.

Comparison: This study will compare substance use and depression symptoms of individuals in two different psychotherapy groups: Integrated Cognitive Behavioral Therapy and Twelve Step Facilitation Therapy. Symptoms and substance use will be compared during the active treatment phase (24 weeks) and for one year following the end of the active treatment.

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Individuals diagnosed with one or more substance use disorders (alcohol, cannabis, and or stimulant abuse/dependence) and an independent co-occurring depressive disorder (major depression or dysthymia) will be included.

Exclusion Criteria:

Individuals with substance induced mood disorders and individuals experiencing persistent psychotic symptoms.
Those with life threatening or unstable medical illness, neurological disorders, or inability to read will be excluded.
Individuals currently prescribed steroids, disulfiram, or long acting benzodiazepines will be excluded.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00108407

Locations


United States, California
	VA San Diego Healthcare System	Recruiting
	San Diego, California, United States, 92161
	Contact: Janet Peyton, MA 858-642-3657 janet.peyton@med.va.gov
	Principal Investigator: Sandra Brown, Ph.D.

Sponsors and Collaborators

Department of Veterans Affairs

More Information

Study ID Numbers:	MHBS-041-99Sa, MHBB-014-04S
First Received:	April 14, 2005
Last Updated:	May 15, 2007
ClinicalTrials.gov Identifier:	NCT00108407
Health Authority:	United States: Federal Government

Keywords provided by Department of Veterans Affairs:

Dual diagnosis

Depression

Substance Use Disorders

Alcohol Use Disorders

Alcohol Abuse/Dependence

Stimulant Abuse/Dependence

Cannabis Abuse/Dependence

Dysthymia

Study placed in the following topic categories:

Depression

Disorders of Environmental Origin

Depressive Disorder, Major

Depressive Disorder

Alcohol Drinking

Marijuana Abuse

Behavioral Symptoms

Mental Disorders

Alcoholism

Substance-Related Disorders

Mood Disorders

Alcohol-Related Disorders

Dysthymic Disorder

Ethanol

Additional relevant MeSH terms:

Pathologic Processes

Disease

ClinicalTrials.gov processed this record on October 07, 2008

Sponsored by:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs
ClinicalTrials.gov Identifier:	NCT00108407